Belgian gene therapy player aims for $99M in IPO; Heron launches Phase II trials of long-acting pain candidate;

> Heron Therapeutics ($HRTX) announced the launch of the Phase II clinical trial of its lead candidate for the prevention of post-operative pain. It utilizes the company's proprietary drug delivery technology and is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. More

> Belgium's gene therapy biotech Celyad announced the terms of its IPO. It aims to raise $99 million through the offer of 1.4 million shares priced at $70.98 per unit. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.